Akcea Therapeutics Inc., of Cambridge, Mass., said it completed enrollment in a phase IIb study of AKCEA-APO(a)-LRx in patients with high Lp(a) and established cardiovascular disease to determine the dose level and frequency of administration for a planned phase III cardiovascular outcome study and to determine the safety and tolerability profile of the antisense drug.